Achilles Therapeutics (ACHL) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Achilles Therapeutics has reported a promising second quarter with a strategic collaboration with Arcturus Therapeutics to develop mRNA cancer vaccines and positive results from Phase I/IIa trials in NSCLC and melanoma. The company has a strong financial position, with $95.1 million to fund operations into 2025. The updates demonstrate the potential of Achilles’ AI-driven precision T cell therapies and the company’s continued progress in oncology.
For further insights into ACHL stock, check out TipRanks’ Stock Analysis page.
